{"id":"long-course-adjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adjuvant chemotherapy is administered following surgery or primary treatment to target micrometastatic disease that may not be clinically detectable. Long course regimens extend the duration of treatment beyond standard protocols, typically involving multiple cycles of chemotherapy drugs designed to maximize cell kill while the patient's performance status allows. This approach aims to improve disease-free and overall survival in high-risk patients.","oneSentence":"Long course adjuvant chemotherapy delivers extended cycles of cytotoxic chemotherapy after primary cancer treatment to eliminate residual disease and reduce recurrence risk.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:23.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of resected colorectal cancer or other solid tumors at high risk of recurrence"}]},"trialDetails":[{"nctId":"NCT04928807","phase":"PHASE3","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-07-20","conditions":"Rectal Cancer","enrollment":231},{"nctId":"NCT07381777","phase":"PHASE2","title":"XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2026-01-31","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":270},{"nctId":"NCT06052332","phase":"NA","title":"Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2024-02-07","conditions":"Locally Advanced Rectal Cancer, Older People","enrollment":230},{"nctId":"NCT04443348","phase":"PHASE2","title":"Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laura M. Spring, MD","startDate":"2020-12-16","conditions":"Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)","enrollment":120},{"nctId":"NCT06850090","phase":"PHASE3","title":"Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-30","conditions":"Rectal Cancer, Rectal Cancer Patients","enrollment":210},{"nctId":"NCT06931808","phase":"PHASE4","title":"Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-03-01","conditions":"Localized Advanced Rectal Adenocarcinoma","enrollment":20},{"nctId":"NCT03714490","phase":"PHASE2","title":"MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2018-10-23","conditions":"Rectal Neoplasms","enrollment":200},{"nctId":"NCT06043999","phase":"NA","title":"Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":"Chemotherapy Effect, Rectal Cancer","enrollment":392},{"nctId":"NCT01558921","phase":"PHASE3","title":"Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2011-06-21","conditions":"Rectal Cancer","enrollment":920},{"nctId":"NCT03957733","phase":"PHASE2, PHASE3","title":"Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.","status":"UNKNOWN","sponsor":"King Abdullah Medical City","startDate":"2017-11-23","conditions":"Rectal Cancer","enrollment":338},{"nctId":"NCT02533271","phase":"PHASE3","title":"Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-08","conditions":"Cancer, Rectum","enrollment":600},{"nctId":"NCT01440413","phase":"NA","title":"Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer","status":"UNKNOWN","sponsor":"Centre Leon Berard","startDate":"2011-12","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT00145769","phase":"PHASE3","title":"A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2001-07","conditions":"Adenocarcinoma of Rectum","enrollment":326}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Long Course Adjuvant Chemotherapy","genericName":"Long Course Adjuvant Chemotherapy","companyName":"Trans Tasman Radiation Oncology Group","companyId":"trans-tasman-radiation-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long course adjuvant chemotherapy delivers extended cycles of cytotoxic chemotherapy after primary cancer treatment to eliminate residual disease and reduce recurrence risk. Used for Adjuvant treatment of resected colorectal cancer or other solid tumors at high risk of recurrence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}